Evidence map›Paper›PMID 25512630›Full record

Trial reportThe Journal of infectious diseases2015

Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin.

Marija Zeremski, Rositsa B Dimova, Samantha Benjamin, Marina S Penney, Martyn C Botfield, Andrew H Talal

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00892697 phase2completednot on this map

#0810010040: Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus Infection: A Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C

TypeinterventionalSponsorWeill Medical College of Cornell UniversityRan2009 to 2012Enrolled15ConditionsHepatitis CArmsTelaprevir, Peginterferon alfa-2a, Ribavirin
NCT03025074 recruitingnot on this map

Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases

Typeobservational_patient_registrySponsorState University of New York at BuffaloRan2013 to 2099Enrolled1,000ConditionsNon-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Marija ZeremskiDivision of Gastroenterology and Hepatology, Weill Cornell Medical College.
Rositsa B DimovaDivision of Gastroenterology, Hepatology, and Nutrition, Department of Medicine Department of Biostatistics, State University of New York at Buffalo, New York.
Samantha BenjaminDivision of Gastroenterology and Hepatology, Weill Cornell Medical College.
Marina S PenneyVertex Pharmaceuticals, Boston, Massachusetts.
Martyn C BotfieldVertex Pharmaceuticals, Boston, Massachusetts.
Andrew H TalalDivision of Gastroenterology and Hepatology, Weill Cornell Medical College Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine.
Cornell University · USVertex Pharmaceuticals (United States) · USUniversity at Buffalo, State University of New York · US

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024996 · NCRR · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2007 to 2011
$49.6M
Clinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0M
NCATS NIH HHS UL1 TR000457NCRR NIH HHS UL1 RR024996NCRR NIH HHS ULI RR024996
6 · The paper itself

Abstract

unlabelledWe assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1 ± 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P = .032) and day 2 (P = .009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P = .023) and peak (P = .034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral. CLINICAL TRIALS REGISTRATION: NCT00892697.

Indexed as

AdolescentAdultAgedAntiviral AgentsChemokine CXCL10FemaleHepacivirusHepatitis C, ChronicHumansInterferon-alphaLiverMaleMiddle AgedOligopeptidesPolyethylene GlycolsRecombinant ProteinsAntiviral AgentsChemokine CXCL10CXCL10 protein, humanInterferon-alphaOligopeptidespeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRibavirintelaprevirchemokinesCXCL10HCVliver inflammation

Identifiers

PMID25512630
PMCPMC4506314
OpenAlexW2024940442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.